NASDAQ: CJMBCallan Jmb Inc Stock
$5.15+0.15 (+3%)
Updated Jul 8, 2025
CJMB Price
$5.15
Fair Value Price
$2.29
Market Cap
$22.88M
52 Week Low
$3.38
52 Week High
$7.76
P/E
N/A
P/B
3.36x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.24
Operating Cash Flow
N/A
Beta
0.4
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CJMB Overview
Callan JMB Inc., through its subsidiary, Coldchain Technology Services, LLC provides thermal management logistics solutions to the life sciences industry. It offers logistics solutions and services utilized for frozen shipping in the life sciences industry, including personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, biopharmaceuticals, infectious substances, and other commodities. The company also provides perishable (non-pharma) client packaging, and technical services. The company was founded in 2006 and is headquartered in Spring Branch, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CJMB's potential to beat the market
- CJMB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important CJMB news, forecast changes, insider trades & much more!
CJMB News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CJMB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CJMB ($5.15) is overvalued by 124.74% relative to our estimate of its Fair Value price of $2.29 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CJMB ($5.15) is not significantly undervalued (124.74%) relative to our estimate of its Fair Value price of $2.29 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CJMB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more CJMB due diligence checks available for Premium users.
Valuation
CJMB fair value
Fair Value of CJMB stock based on Discounted Cash Flow (DCF)
Price
$5.15
Fair Value
$2.29
Overvalued by
124.74%
CJMB ($5.15) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CJMB ($5.15) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CJMB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.36x
Industry
7.22x
CJMB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CJMB's financial health
Profit margin
Revenue
$1.4M
Net Income
-$1.2M
Profit Margin
-85.6%
Assets to liabilities
Assets
$8.5M
Liabilities
$1.6M
Debt to equity
0.24
CJMB's short-term assets ($6.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CJMB's short-term assets ($6.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CJMB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
-$15.0k
Financing
$4.7M
CJMB vs App Stocks
Callan Jmb Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.